[1] Siegel RL, Giaquinto AN, Jemal A.Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. [2] Viale PH.The American Cancer Society's Facts & Figures: 2020 Edition[J]. J Adv Pract Oncol, 2020, 11(2): 135-136. [3] Ying H, Dey P, Yao W, et al.Genetics and biology of pancreatic ductal adenocarcinoma[J]. Genes Dev, 2016, 30(4): 355-385. [4] Wehr AY, Furth EE, Sangar V, et al.Analysis of the human pancreatic stellate cell secreted proteome[J]. Pancreas, 2011, 40(4): 557-566. [5] Binenbaum Y, Na'ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma[J]. Drug Resist Updat, 2015, 23: 55-68. [6] Li X, Shepard HM, Cowell JA, et al.Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression[J]. Clin Cancer Res, 2018, 24(19): 4798-4807. [7] Bandula S, Punwani S, Rosenberg WM, et al.Equilibrium contrast-enhanced CT imaging to evaluate hepatic fibrosis: initial validation by comparison with histopathologic sampling[J]. Radiology, 2015, 275(1): 136-143. [8] Jablonowski R, Wilson MW, Do L, et al.Multidetector CT measurement of myocardial extracellular volume in acute patchy and contiguous infarction: validation with microscopic measurement[J]. Radiology, 2015, 274(2): 370-378. [9] Sofue K, Ueshima E, Masuda A, et al.Estimation of pancreatic fibrosis and prediction of postoperative pancreatic fistula using extracellular volume fraction in multiphasic contrast-enhanced CT[J]. Eur Radiol, 2022, 32(3): 1770-1780. [10] Fukukura Y, Kumagae Y, Higashi R, et al.Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma[J]. Eur Radiol, 2020, 30(3): 1679-1689. [11] Fujita N, Ushijima Y, Itoyama M, et al.Extracellular volume fraction determined by dual-layer spectral detector CT: Possible role in predicting the efficacy of preoperative neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma[J]. Eur J Radiol, 2023, 162: 110756. [12] Noid G, Godfrey G, Hall W, et al.Predicting Treatment Response From Extracellular Volume Fraction for Chemoradiation Therapy of Pancreatic Cancer[J]. Int J Radiat Oncol Biol Phys, 2023, 115(3): 803-808. [13] Shi Y, Liu Y, Gao F, et al.Pancreatic Stiffness Quantified with MR Elastography: Relationship to Postoperative Pancreatic Fistula after Pancreaticoenteric Anastomosis[J]. Radiology, 2018, 288(2): 476-484. [14] Park HJ, Kim HJ, Kim KW, et al.Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT[J]. Eur Radiol, 2020, 30(9): 4772-4782. [15] Su Q, Wang Q, Zhang H, et al.Computed tomography findings of small bowel gastrointestinal stromal tumors with different histologic risks of progression[J]. Abdom Radiol (NY), 2018, 43(10): 2651-2658. [16] Uzunparmak B, Sahin IH.Pancreatic cancer microenvironment: a current dilemma[J]. Clin Transl Med, 2019, 8(1): 2. [17] Sarantis P, Koustas E, Papadimitropoulou A, et al.Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy[J]. World J Gastrointest Oncol, 2020, 12(2): 173-181. [18] Tomasek JJ, Gabbiani G, Hinz B, et al.Myofibroblasts and mechano-regulation of connective tissue remodelling[J]. Nat Rev Mol Cell Biol, 2002, 3(5): 349-363. [19] Luo W, Zhang T.Cancer-associated fibroblasts: A key target to snatch victory from defeat in therapy resistance associated with the pancreatic cancer stroma[J]. Cancer Lett, 2023, 567: 216279. [20] Ashrafizadeh M, Farhood B, Eleojo Musa A, et al.The interactions and communications in tumor resistance to radiotherapy: Therapy perspectives[J]. Int Immunopharmacol, 2020, 87: 106807. [21] Shi M, Yu DH, Chen Y, et al.Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance[J]. World J Gastroenterol, 2012, 18(8): 840-846. [22] Liu F, Qi L, Liu B, et al.Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis[J]. PLoS One, 2015, 10(3): e0116683. [23] McAndrews KM, Chen Y, Darpolor JK, et al. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer[J]. Cancer Discov, 2022, 12(6): 1580-1597. [24] Cheng SH, Cheng YJ, Jin ZY, Xue HD.Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy[J]. Eur J Radiol, 2019, 113: 188-197. [25] Barreto SG, Dirkzwager I, Windsor JA, Pandanaboyana S.Predicting post-operative pancreatic fistulae using preoperative pancreatic imaging: a systematic review[J]. ANZ J Surg, 2019, 89(6): 659-665. [26] Serai SD, Yin M.MR Elastography of the Abdomen: Basic Concepts[J]. Methods Mol Biol, 2021, 2216: 301-323. [27] Guo SL, Su LN, Zhai YN, et al.The clinical value of hepatic extracellular volume fraction using routine multiphasic contrast-enhanced liver CT for staging liver fibrosis[J]. Clin Radiol, 2017, 72(3): 242-246. [28] Li X, Liang D, Meng J, et al.Development and Validation of a Novel Computed-Tomography Enterography Radiomic Approach for Characterization of Intestinal Fibrosis in Crohn's Disease[J]. Gastroenterology, 2021, 160(7): 2303-2316 e2311. [29] Janssen BV, Verhoef S, Wesdorp NJ, et al.Imaging-based Machine-learning Models to Predict Clinical Outcomes and Identify Biomarkers in Pancreatic Cancer: A Scoping Review[J]. Ann Surg, 2022, 275(3): 560-567. [30] Jiang Y, Liang X, Han Z, et al.Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study[J]. Lancet Digit Health, 2021, 3(6): e371-e382. [31] Kim PK, Hong YJ, Sakuma H, et al.Myocardial Extracellular Volume Fraction and Change in Hematocrit Level: MR Evaluation by Using T1 Mapping in an Experimental Model of Anemia[J]. Radiology, 2018, 288(1): 93-98. [32] Whatcott CJ, Han H, Von Hoff DD.Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction[J]. Cancer J, 2015, 21(4): 299-306. [33] Jiang H, Hegde S, Knolhoff BL, et al.Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy[J]. Nat Med, 2016, 22(8): 851-860. [34] Laklai H, Miroshnikova YA, Pickup MW, et al.Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression[J]. Nat Med, 2016, 22(5): 497-505. [35] Levental KR, Yu H, Kass L, et al.Matrix crosslinking forces tumor progression by enhancing integrin signaling[J]. Cell, 2009, 139(5): 891-906. [36] Northey JJ, Przybyla L, Weaver VM.Tissue Force Programs Cell Fate and Tumor Aggression[J]. Cancer Discov, 2017, 7(11): 1224-1237. [37] Sun X, He X, Zhang Y, et al.Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism[J]. Gut, 2022, 71(1): 129-147. [38] Whatcott CJ, Diep CH, Jiang P, et al.Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer[J]. Clin Cancer Res, 2015, 21(15): 3561-3568. |